Trials / Withdrawn
WithdrawnNCT04841538
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
An Open-label, Multicenter, Multicohort Phase 1b/2 Clinical Trial of ES101 in Patients With Advanced Malignant Thoracic Tumors
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Elpiscience Biopharma, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor efficacy of ES101 in advanced malignant thoracic tumors, including NSCLC and SCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ES101 | The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2023-12-01
- Completion
- 2024-05-01
- First posted
- 2021-04-12
- Last updated
- 2022-04-29
Source: ClinicalTrials.gov record NCT04841538. Inclusion in this directory is not an endorsement.